BACKGROUND: Diabetes is a major risk factor for coronary heart disease in women and event rates increase substantially after the menopause. Observational studies have suggested that estrogens may provide cardioprotection by regulating endothelial nitric oxide synthase. METHODS: In order to examine the effect of hormone replacement therapy (HRT) on endothelium-dependent and -independent vascular relaxation in post-menopausal women with type 2 diabetes, an open study was conducted in which gluteal biopsies were collected from 17 women before and after 6 months of transdermal 17β-estradiol (80 µg twice weekly) in combination with oral norethisterone (1 mg daily). Small arteries (<550 µm) were dissected from fat and mounted on a wire myograph for assessment of relaxation in response to acetylcholine (ACh), bradykinin (BK) and sodium nitroprusside (SNP). RESULTS: Maximal relaxation responses to ACh, BK and SNP in women with diabetes and non-diabetic control subjects were 52 ⍨ 8 versus 96 ⍨ 2% (P < 0.05), 76 ⍨ 7 versus 97 ⍨ 1%, (P < 0.05) and 91 ⍨ 2 versus 98 ⍨ 1% (P < 0.05) respectively. After 6 months of HRT, maximal relaxation responses to ACh, BK and SNP in women with diabetes (compared with pre-HRT) were: 88 ⍨ 4 (P < 0.05), 93 ⍨ 3 (P < 0.05) and 98 ⍨ 1% (P < 0.05) respectively. At baseline and after HRT, EC 50 (concentration required to obtain 50% of maximum response) data exhibited similar changes. CONCLUSIONS: HRT had potentially beneficial effects on vascular relaxation. Data were consistent with improvements in endothelial function, vascular smooth muscle function, or both. Controlled studies are required to confirm and extend these findings.
Introduction
Coronary heart disease (CHD) is the most important cause of death in type 2 diabetes mellitus. Middle-aged women with diabetes have a five times greater risk of CHD than their male counterparts, with a relative risk of death from CHD of 1.5-2.5 in men (Kessler, 1971; Kannel and McGee, 1979 ) and 1.7-4.0 in women (Barrett-Connor et al., 1991) A number of inter-related phenotypic abnormalities underpinned by resistance to insulin-mediated glucose uptake including hyperglycaemia, hypertension, dyslipidaemia, and a prothrombotic state (Cleland et al., 1998) are linked via oxidative stress (Stehouwer et al., 1997; Laight et al., 1999) and inflammation (Pickup et al., 1997) with accelerated CHD in type 2 diabetes. Endothelial dysfunction plays a central role in these processes (Nitenberg et al., 1993; Williams et al., 1996) . A growing body of evidence suggests that the vascular endothelium in type 2 diabetes produces abnormally raised levels of vasoconstrictors (Nugent et al., 1996; Laight et al., 1999) and procoagulants (Collier et al., 1992) and has a reduced capacity to synthesize nitric oxide (NO) and other vasodilators (Hsueh et al., 1997; Honing et al., 1998) . In experimental models of atherosclerosis, reduced formation of NO is compounded by increased endothelial production of superoxide by enzymes including NO synthase, particularly under conditions of co-factor deficiency (Beckman and Koppenol, 1996; Wever et al., 1997) . This, in turn, reacts with NO to form peroxynitrite, which may disrupt metabolic processes in adjacent tissues (Pryor and Squadrito, 1995) . These metabolic perturbations may increase peripheral resistance, decrease tissue perfusion and ultimately contribute to the development of CHD and other forms of cardiovascular disease.
In non-diabetic women prior to the menopause it has been suggested on the basis of observational data that hormone replacement therapy (HRT) may be cardioprotective (Grodstein et al., 1996) . Basal release of NO from coronary endothelial cells, known to control basal vascular tone and antagonize prothrombotic and proinflammatory processes (Vallance, 1998) , is enhanced by estrogen which can also up-regulate endothelial NO synthase (Caulin-Glaser et al., 1997) . The only large randomized placebo-controlled study to date examining the effects of estrogen in the prevention of CHD is the Heart and Estrogen/progestin Replacement Study (HERS) which was conducted in relatively elderly women (mean age 67 years) in the secondary prevention setting (Hulley et al., 1998) . No overall beneficial effect of the HRT regimen based on conjugated equine estrogens and medroxyprogesterone acetate was detected and an early excess of thrombotic events was observed. There are as yet no randomized data on primary prevention of CHD in middle-aged women.
In addition to increasing NO synthesis, estrogen has potentially favourable effects on lipoprotein profiles (Andersson et al., 1997) , carbohydrate metabolism (Brussard et al., 1997) and vascular reactivity (Gilligan et al., 1994; Mendelsohn and Karas, 1999) . As multiple pathophysiological processes contribute to coronary atherosclerosis and thrombosis in type 2 diabetes, it is important that the effects of different forms of HRT on each of these processes are delineated in order to optimize design of future HRT-based primary prevention studies in type 2 diabetes.
We have recently suggested that HRT regimens based on 17β-estradiol and progestagen (norethisterone) may be more rational for women with diabetes than those based on synthetic conjugated estrogens (Sattar et al., 1999a,b) . In addition, we have hypothesized that women with type 2 diabetes stand to benefit more from any HRT cardioprotection than their nondiabetic counterparts on the basis of their higher absolute baseline risk (Sattar et al., 1998) . However, owing mainly to concerns regarding effects on glycaemic control, diabetes remains listed as a relative contraindication to HRT and rates of prescription and uptake are low (Feher and Isaacs, 1996) In the present study, wire myography was used to assess the effect on small vessel endothelial function of 6 months of continuous combined HRT, consisting of transdermal 17β-estradiol and oral norethisterone, in women with type 2 diabetes.
Methods
The study conformed to the principles outlined in the Declaration of Helsinki and was approved by the local ethical review committee of the West Glasgow Hospitals University NHS Trust.
Patients and control subjects
All subjects gave prior written, informed consent. Seventeen postmenopausal women with type 2 diabetes, good glycaemic control [haemaglobin (Hb)A1c Ͻ6.5%], blood pressure (BP) Ͻ150/95 mmHg and total cholesterol Ͻ5.2 mmol/l were recruited from clinics at the Diabetes Centre, Gartnavel General Hospital, Glasgow. Three nondiabetic women of similar age, body mass index (BMI) and BP were also studied. None of the subjects had previously received HRT and all had been amenorrhoeic for at least one year. None had evidence of microvascular complications, microalbuminuria or symptoms of ischaemic heart disease. None were on statin therapy. Those on aspirin and/or stable monotherapy with metformin, sulphonylureas or dihydropyridines only were included and remained on these treatments throughout the trial with no change in dose.
498
Each woman was invited to attend for gluteal biopsy before and after 6 months of treatment with continuous combined HRT consisting of 80 µg estradiol patches applied twice weekly in combination with 1 mg oral norethisterone daily. Pharmacological assessment of vascular function was assessed ex vivo using wire myography on the same day as biopsy after dissection of subcutaneous resistance arteries.
Subcutaneous gluteal fat biopsies
Skin and subcutaneous fat biopsies were taken as previously described (McNally et al., 1995; Padmanabhan et al., 1999) after application of 1% lidocaine local anaesthesia, from the right (pre-HRT) and left (post-HRT) gluteal region. Each biopsy measured approximately 2ϫ1ϫ1 cm.
Vessel preparation
Abnormal endothelial function has its greatest effect on the circulation at the level of the resistance vasculature (100-400µm) at which point a 50% drop in pre-capillary pressure occurs (Davis et al., 1986) . Small arteries (Ͻ550µm) were therefore dissected from biopsied fat under a microscope and mounted on two 40 µm stainless steel wires on a Mulvany/Halpern myograph allowing isometric force measurements to be made (Davis et al., 1986) . Where possible, two or three vessels from each patient were investigated simultaneously under identical conditions. The vessels were maintained at 37 Ϯ 0.5°C in 95% O 2 /5% CO 2 to a pH of 7.4 in physiological salt solution (PSS) with the following composition: NaCl 118.4, NaHCO 3 25, KCl 4.7, KH 2 PO 4 1.2, CaCl 2 2.5, MgSO 4 7H 2 O 1.2 and glucose 11 mmol/l.
Wire myography
The method used was that of Mulvany (Mulvany et al., 1978) . Following an equilibration period, each vessel was stretched in a step-wise fashion to allow an estimate of the transmural pressure required to stretch the relaxed vessel in vivo to the given internal circumference. Finally, each vessel was set to 90% of its own internal circumference at an effective pressure of 100 mmHg (previous studies have shown that a maximal force is generated at this setting) (Mulvany et al., 1978) . Following this normalization procedure, the vessels were left for a further 1 h and then exposed to a high (123 mmol/l) concentration of potassium (solution identical to PSS except that sodium is replaced by potassium on an equimolar basis) for a series of 5 min periods until repeatable maximal contractions were achieved. Acetylcholine (ACh) and bradykinin (BK) act via receptor-mediated mechanisms within endothelial cells to promote synthesis/release of NO which activates guanylate cyclase on adjacent smooth muscle to cause vascular relaxation. Sodium nitroprusside (SNP) donates NO directly to smooth muscle cells and therefore does not require the presence of intact endothelial mechanisms. Cumulative concentration response curves were carried out according to the following protocol:
(i) noradrenaline (NA: 10 -8 to 3ϫ10 -5 mol/l) (ii) ACh (10 -8 to 10 -4 mol/l) then BK (10 -10 to 3ϫ10 -6 mol/l) in preconstricted vessels (NA: 10 -5 mol/l) (iii) SNP (10 -9 to 10 -4 mol/l) in preconstricted vessels (NA: 10 -5 mol/l).
Vessels were left for 30 min between assessment of dose-response curves. It has previously been shown that contraction responses of human vessels to noradrenaline are stable over 6 h and that 30 min between curves is sufficient to achieve repeatable contraction responses (Hillier et al., 1999) Drugs ACh, BK, NAand SNP were obtained from the Sigma Chemical Company, Poole, Dorset, UK. All drugs were dissolved in distilled water and diluted to the final bath concentration with PSS. 
Statistical analysis
Relaxation data are expressed as percentage change (%) from maximum noradrenaline-induced contraction. Where more than one vessel from a single biopsy was successfully mounted, data were treated as replicates and a mean response used in further analysis. Results are expressed as mean Ϯ SEM. Maximal relaxation response and EC 50 (concentration required to obtain 50% of maximum response) were used as summary measures (Matthews et al., 1990) . Statistical comparison was performed after checking appropriate distribution of data using unpaired (control versus pre-or post-HRT) and paired (pre-versus post-HRT) t-tests with P Ͻ 0.05 considered statistically significant. Simple correlation was used to examine relationships between vascular responses and baseline demographic and metabolic data.
Results
Characteristics of women recruited to the study were as follows: age 61 Ϯ 3.7 years, BMI 30.3 Ϯ 7.03 kg/m 2 , HbA1c 6.2 Ϯ 1.25%, total cholesterol 5.5 Ϯ 0.94 mmol/l, blood pressure (BP) systollic/diastollic 130 Ϯ 18.1/86 Ϯ 13.1 mmHg). Prior to treatment, 26 vessels from 17 biopsies (i.e. nine replicates) from women with type 2 diabetes were dissected and successfully mounted, while six vessels were obtained for comparison from the three non-diabetic women. Biopsies were well-tolerated and all women consented to a repeat procedure. At follow-up, 36 vessels were obtained from 17 biopsies from the same women.
BMI and glycaemic control were similar at baseline and follow-up.
Pre-HRT
In comparison with vessels from control subjects, vessels from women with type 2 diabetes exhibited impaired vasorelaxation to both endothelium-dependent and endothelium-independent agonists (Table I, Figures 1-3) . No correlation was observed between vasorelaxation responses and HbA1c or total cholesterol. There was a trend towards improved relaxation in women with a BMI Ͼ30 m/kg 2 . However, the small numbers prevent further meaningful analysis of the results at this stage. 
Post-HRT
Following 6 months HRT, responses in arteries from patients with type 2 diabetes were augmented compared with baseline responses (Table I, Figures 1-3) . Post-HRT responses were similar to those observed in vessels from control subjects.
Discussion
In the present study we observed augmentation of responses ex vivo to both endothelium-dependent and -independent agonists in subcutaneous resistance arteries from post-menopausal women with type 2 diabetes treated with continuous combined HRT for 6 months. Indeed, responses after HRT to all agonists were similar to those observed in a small number of nondiabetic control subjects. The limitations of these data are recognized, but recruiting non-diabetic women to act as control subjects in this type of study is extremely difficult. Post-menopausal women with type 2 diabetes are at high risk of CHD and the importance of endothelial dysfunction in atherogenesis and thrombosis is increasingly recognized (Ross, 1993) . The finding of impaired responses to both endotheliumdependent and -independent agonists was not unexpected. It is now acknowledged on the basis of studies using a variety of invasive and non-invasive techniques [forearm plethysmography (McVeigh et al., 1992; Williams et al., 1996) , flowmediated vasodilation (Goodfellow et al., 1996) , laser-doppler iontophoresis (Morris et al., 1995) and wire myography (Cipolla et al., 1996) ] that those with type 2 diabetes have dysfunctional endothelium in both conduit and resistance arteries. Indeed, this also appears to be the case in insulinresistant first degree relatives (Caballero et al., 1999; Balletshofer et al., 2000) .
Abnormal responses to endothelium-independent agonists have been reported in type 2 diabetes by other workers (Flavahan, 1992; McVeigh et al., 1992; Williams et al., 1996) . In the current study it was found that vessels from women with diabetes were 20-fold less sensitive to SNP than those of controls (a similar magnitude to that observed by Williams) (Williams et al., 1996) . Interpretation of abnormal 'endothelium-dependent' responses is difficult in this situation, as the defect cannot be attributed to the endothelial monolayer. It has been suggested that heterogeneity of responses to sodium nitroprusside between studies can be explained on the basis of disease duration with progressive vascular damage affecting first ACh responses and subsequently those to BK and finally SNP (Flavahan, 1992) . However, in the present study, SNP responses were impaired to a much greater extent than those to BK.
In contradistinction to the notion of progressive vascular damage, the subjects had low HbA1c values and a median disease duration of only 3 years. However, type 2 diabetes is often preceded by years of insulin resistance and glucose intolerance (Goyder and Irwig, 1998) . It may be the case that endothelium-derived mediators such as peroxynitrite, formed under conditions of oxidative stress, result in damage to the smooth muscle layer at a relatively early stage in the course of diagnosed disease. Furthermore, it is now recognized that advanced glycosylation end-products are deposited in a wide variety of tissues over a relatively short time course (Schmidt et al., 1999) . This represents an alternative possible mechanism for abnormal endothelium-independent responses, although the reversibility of abnormal responses observed over 6 months in the present study favours a functional rather than structural explanation. A further possible mechanism is an abnormality 500 at the level of smooth muscle guanylate cyclase, as has recently been proposed by Reaven (Zavaroni et al., 2000) .
Circumstantial evidence is in favour of a positive effect of sex hormones on vascular function. For example, the rate of decline in acetylcholine vasodilatation with age is attenuated in premenopausal women in a manner that appears to mirror protection from CHD (Taddei et al., 1996) . Intra-brachial responses to the NO synthase inhibitor N G -monomethyl-Larginine (L-NMMA) were augmented in non-diabetic postmenopausal women after a brief period of HRT (Sudhir et al., 1996) . However, it appears that there have been no previous reports of augmented endothelium-independent responses after HRT in women with or without type 2 diabetes.
It could be possible that the augmentation of vascular responses observed after HRT in the present study was not a genuine effect. Owing to the nature of the design, bias cannot formally be excluded-although it should be noted that true double-blinding is notoriously difficult in any study of HRT versus placebo. As formal time controls were not incorporated, it remains conceivable that the effect observed was an artefact of a confounding and unrecognized technical factor. However, variations in responses to acetylcholine, sodium nitroprusside and bradykinin in previous studies have been small when compared with the effect size reported herein (Hillier et al., 1999) . Another technical factor worthy of consideration, which may influence results, was the preconstriction agent. The major difference between that study and the present one was use of thromboxane rather than noradrenaline for preconstriction; it is uncertain which approach is more physiologically relevant.
Women participating in the present study continued on aspirin and stable monotherapy with sulphonylureas, metformin or dihydropyridines. Even if it had been considered ethical to discontinue such medication over a 6 month period, the data would have been both subject to carryover effects and would not be applicable to the majority of women with type 2 diabetes. In women who continued on aspirin, inhibition of the cyclo-oxygenase pathway may have made vascular relaxation responses to acetycholine smaller and more NOdependent than in other subjects, but this would not have affected the pre-and post-treatment comparison. Although there was a tendency for the vascular reactivity to be improved in the obese women (BMI Ͼ30m/kg 2 ), there was no weight change in the women during the study, and so this factor was not thought to influence the results. It will be of interest to investigate this further in the future.
If HRT did augment relaxation to endothelium-dependent agonists, possible mechanisms for this include up-regulation of endothelial NO synthase (Sudhir et al., 1996; Caulin-Glaser et al., 1997) , an indirect effect on endothelial function by virtue of anti-inflammatory properties or favourable effects on insulin sensitivity, lipoprotein profiles and oxidative stress or a reduction in endothelin-1. In addition, a direct or indirect effect leading to increased NO bioavailability by inhibiting its metabolism (Wever et al., 1997) is under investigation. These hypotheses cannot be addressed within the design of the present study.
Data from a study by our own group, taken together with data from the literature (Sattar et al., 1999a,b) indicate that norethisterone has hepatically-mediated anti-inflammatory effects that may, in turn, have downstream favourable effects on endothelial function. In keeping with this notion, it has recently been reported that C-reactive protein levels-an index of chronic, low grade inflammation-show high correlation with basal endothelial NO synthesis/release (Cleland et al., 2000) . Inflammation is increasingly recognized as a determinant of CHD risk (Ridker et al., 1997) and it is attractive to speculate that anti-inflammatory properties of different HRT preparations may be relevant to their effects on CHD risk.
The observation of reduced sensitivity to bradykinin in type 2 diabetes may be clinically relevant to the beneficial effects of angiotensin converting enzyme (ACE) inhibitors in type 2 diabetes (Anonymous, 2000) . Unlike ACh, BK is an endogenous vasodilator with a functional role in modulating vascular tone in resistance arteries. There is some evidence that estrogen can upregulate the endothelial renin-angiotensin system and thereby potentiate BK responses. Recent descriptions of non-ACE pathways for angiotensin II formation have recently reemphasised the potential cardiovascular importance of BK potentiation rather than inhibition of angiotensin II formation during ACE inhibition (Mulvany et al., 1978) . Thus, reducing BK breakdown in patients with type 2 diabetes via ACE inhibition might provide a complementary strategy to HRT for restoring endothelial function.
Recent studies suggest that a major component of relaxation responses to both BK and ACh is dependent on release of a further, as yet unidentified substance known as endotheliumderived hyperpolarizing factor (EDHF) (Coats et al., 2000) , whose role may be influenced by female sex steroids (Hansen et al., 1996; Otter and Austin, 1998; Ayajiki et al., 1999) . Full delineation of the effects of HRT on vascular function will require use of specific EDHF inhibitors/blockers. In summary, in this small study utilizing careful ex vivo assessments, HRT consisting of continuous combined transdermal 17β-estradiol and oral norethisterone resulted in potentially beneficial effects on vascular relaxation in postmenopausal women with type 2 diabetes. Data were consistent with improvements in endothelial function, vascular smooth muscle function, or both. On the basis of the present data, HRT regimen consisting of transdermal estradiol with continuous oral norethisterone are attractive candidates to enter primary prevention CHD trials in post-menopausal women with type 2 diabetes.
